 |
|
|
| |
Outcomes of 48 Weeks of Therapy and Subsequent 24-Week Post-Treatment Period With Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a in Chronic Hepatitis B Virus Infection: Findings From the MARCH Study
|
| |
| |
European Association for the Study of the Liver (EASL) Congress;
7-10 May 2025; Amsterdam, The Netherlands
oral presentation may 9
|
| |
|
|
|
|
|
